Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation

British Journal of Haematology

Volumn 128, Issue 3, 2005, Pages 351-359

  Dey, Bimalangshu R ^a   McAfee, Steven ^a   Colby, Christine ^a   Cieply, Kathy ^b   Caron, Martin ^a   Saidman, Susan ^a   Preffer, Frederic ^a   Shaffer, Juanita ^c   Tarbell, Nancy ^a   Sackstein, Robert ^a   Sachs, David ^c   Sykes, Megan ^c   Spitzer, Thomas R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Allogeneic; Chimaerism; Conditioning; Non myeloablative; Stem cell transplant

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; HLA ANTIGEN; SIPLIZUMAB; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CHIMERA; DONOR; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; IRRADIATION; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; T LYMPHOCYTE; THYMUS;

ADULT; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTE TRANSFUSION; MIDDLE AGED; REMISSION INDUCTION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 13444310503     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05328.x     Document Type: Article

References (25)

1. + suppressor T-cells. Cancer Res, 49, 1649-1654.
2. Ballen, K.K., Becker, P.S., Emmons, R.V., Fitzgerald, T.J., Hsieh, C.C., Liu, Q., Heyes, C., Clark, Y., Levy, W., Lambert, J.F., Chiafari, F., Szymanski, I., Rososhansky, S., Popovsky, M.A., Stewart, F.M. & Quesenberry, P.J. (2002) Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood, 100, 442-450.
3. Barnes, D.W., Corp, M.J., Loutit, J.F. & Neal, F.E. (1956) Treatment of murine leukemia with x-rays and homolgous bone marrow. Br Med J, 2, 626-627.
4. Bortin, M.M., Rimm, A.A. & Saltzstein, E.G. (1973) Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science, 179, 811-813.
5. Bortin, M.M., Truitt, R.L., Rimm, A.A. & Bach, F.H. (1979) Graft-versus-leukemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature, 281, 490-491.
6. Botnick, L.E., Hannon, E.G., Vigneulle, R. & Hellman, S. (1981) Differential effects of cytotoxic agents on hematopoietic progenitors. Cancer Res, 41, 2338-2342.
7. Buhler, L.H., Spitzer, T.R., Sykes, M., Sachs, D.H., Delmonico, F.L., Tolkoff-Rubin, N., Saidman, S.L., Sackstein, R., McAfee, S., Dey, B., Colby, C. & Cosimi, A.B. (2002) Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation, 74, 1405-1409.
8. Cesano, A., Visonneau, S., Jeglum, K.A., Owen, J., Wilkinson, K., Carner, K., Reese, L. & Santoli, D. (1996) Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res, 56, 3021-3029.
9. Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E.J., Tisdale, J., Dunbar, C., Linehan, W.M., Young, N.S. & Barrett, A.J. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med, 343, 750-758.
10. Dey, B.R., McAfee, S., Colby, C., Sackstein, R., Saidman, S., Tarbell, N., Sachs, D.H., Sykes, M. & Spitzer, T.R. (2003) Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant, 9, 320-329.
11. Down, J.D. & Ploemacher, R.E. (1993) Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol, 21, 913-921.
12. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L. & Niederwieser, D. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood, 86, 2041-2050.
13. Kraus, A.B., Shaffer, J., Toh, H.C., Preffer, F., Dombkowski, D., Saidman, Colby, C., George, R., McAfee, S., Sackstein, R., Dey, B., Spitzer, T.R. & Sykes, M. (2003) Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following non-myeloablative allogeneic bone marrow transplantation. Exp Hematol, 31, 609-621.
14. Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., van Oers, M.H., Fibbe, W., Russell, I., Donk, N.W. & Verdonck, L.F. (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol, 18, 3031-3037.
15. Mapara, M.Y., Yong-Mi, K., Sheng-Ping, W., Bronson, R., Sachs, D.H. & Sykes, M. (2002) Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood, 100, 1903-1909.
16. McSweeney, P.A., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molin, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E., Georges, G.E., Grumet, F.C., Kiem, H.P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 97, 3390-4000.
17. O'Donnell, P.V., Luznik, L., Jones, R.J., Vogelsang, G.B., Leffell, M.S., Phelps, M., Rhubart, P., Cowan, K., Piantados, S. & Fuchs, E.J. (2002) Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using post-transplantation cyclophosphamide. Biol Blood Marrow Transplant, 8, 377-386.
18. Pelot, M.R., Pearson, D.A., Swenson, K., Zhao, G., Sachs, J., Yang, Y.G. & Syke, M. (1999) Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant, 5, 133-143.
19. Porter, D.L., Connors, J.M., Van Deerlin, V.M., Duffy, K.M., McGarigle, C, Saidman, S.L., Leonard, D.G. & Antin, J.H. (1999). Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol, 17, 1234-1239.
20. Rubio, M.T., Kim, Y.M., Sachs, T., Mapara, M., Zhao, G. & Sykes, M. (2003) Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood, 102, 2300-2307.
21. Spitzer, T.R., Delmonico, F., Tolkoff-Rubin, N., McAfee, S., Sackstein, R., Saidm, S., Colby, C., Sykes, M., Sachs, D.H. & Cosimi, A.B. (1999) Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation, 68, 480-484.
22. Spitzer, T.R., McAfee, S., Sackstein, R., Colby, C., Toh, H.C., Multani, P., Saidman, S., Weyouth, D.W., Preffer, F., Poliquin, C., Foley, A., Cox, B., Andrews, D., Sachs, D.H. & Sykes, M. (2000) The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant, 6, 309-320.
23. Spitzer, T.R., McAfee, S.L., Dey, B.R., Colby, C., Hope, J., Grossberg, H., Preffer, F., Shaffer, J., Alexander, S.I., Sachs, D.H. & Sykes, M. (2003) Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75, 1748-1752.
24. Sykes, M., Romick, M.L. & Sachs, D.H. (1990) Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci U S A, 87, 5633-5637.
25. Weiden, P.L., Flournoy, N., Thomas, E.D., Prentice, R., Fefer, A., Buckner, C.D. & Storb, R. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med, 300, 1068-1073.